글로벌 폐포단백증 약물 시장 - 2028년까지의 산업 동향 및 예측

시장 분석 및 통찰력: 글로벌 폐포 단백증 약물 시장

폐포 단백증 약물 시장은 2021-2028년 예측 기간에 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 위에서 언급한 예측 기간에 시장이 7.20%의 CAGR로 성장할 것으로 분석합니다.

폐포 단백증(PAP)은 폐의 기도인 폐포에 표면활성제 유래 지단백질이 비정상적으로 축적되는 희귀한 폐 질환입니다. 축적으로 인해 산소가 혈류에 도달하지 못해 호흡이 힘들어집니다. 호흡곤란, 얼굴이 파랗게 변하는 증상, 기침, 체중 감소, 전반적인 피로 등이 모두 흔한 PAP 증상입니다.

주로 남성 인구에서 폐포 단백증의 유병률 증가와 노령 인구 증가는 시장 성장률에 영향을 미치는 주요 요인입니다. 또한 규제 당국의 특별 지정 증가, 의료비 증가 , 희귀 질환과 이용 가능한 치료법에 대한 인식을 확산하기 위한 정부 및 민간 기관의 이니셔티브 증가는 폐포 단백증 약물 시장을 확대할 요인입니다. 폐 질환 위험을 증가시킬 흡연 습관 채택률의 급증과 효과적인 치료를 위한 약물 수요 증가와 같은 다른 요인은 시장 성장률을 완화할 것입니다.

2021~2028년 예측 기간 동안 제약 회사의 연구 개발 활동과 전략적 협력이 증가함에 따라 폐포 단백증 약물 시장에 유익한 기회가 제공될 것입니다.

However, high cost associated with drugs and lacks of effective diagnostics are the factors that will hinder the market growth. Less healthcare expenditure in some lower and upper income countries will further challenge the pulmonary alveolar proteinosis drug market in the forecast period mentioned above.

This pulmonary alveolar proteinosis drug market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pulmonary alveolar proteinosis drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Pulmonary Alveolar Proteinosis Drug Market Scope and Market Size

The pulmonary alveolar proteinosis drug market is segmented on the basis of disease type, drug type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• On the basis of disease type, the pulmonary alveolar proteinosis drug market is segmented into autoimmune pulmonary alveolar proteinosis (aPAP), congenital and secondary pulmonary alveolar proteinosis (PAP).
• On the basis of drug type, the pulmonary alveolar proteinosis drug market is segmented into rituximab and others.
• On the basis of treatment, the pulmonary alveolar proteinosis drug market is segmented into whole lung lavage, lung transplant, plasmapheresis, GM-CSF replacement therapy and others.
• On the basis of diagnosis, the pulmonary alveolar proteinosis drug market is segmented into blood tests, bronchoscopy, imaging tests, pulmonary function tests, biopsy and others.
• On the basis of route of administration, the pulmonary alveolar proteinosis drug market is segmented into oral, inhalation and others.
• On the basis of end-users, the pulmonary alveolar proteinosis drug market is segmented into hospital, specialty clinics, homecare and others.
• The pulmonary alveolar proteinosis drug market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.

Pulmonary Alveolar Proteinosis Drug Market Country Level Analysis

Pulmonary alveolar proteinosis drug market is analyzed and market size information is provided by the country, disease type, drug type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the pulmonary alveolar proteinosis drug market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the pulmonary alveolar proteinosis drug market due to the presence of major key players, high disposable income and well-developed healthcare sector in this region. Asia-Pacific is expected to grow during the forecast period of 2021-2028 due to the increasing research and development activities, rising investment in the healthcare sector and growing government support.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Pulmonary alveolar proteinosis drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Pulmonary Alveolar Proteinosis Drug Market Share Analysis

폐포 단백증 약물 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 임상 시험 파이프라인, 제품 승인, 특허, 제품 폭과 폭, 응용 분야 우세, 기술 수명선 곡선이 포함됩니다. 위에 제공된 데이터 포인트는 글로벌 폐포 단백증 약물 시장 조사와 관련된 회사의 초점에만 관련됩니다.

폐포 단백증 약물 시장 보고서에서 다루는 주요 기업으로는 Savara Inc., Partner Therapeutics, Inc., F. Hoffmann-La Roche Ltd, Sanofi, Novartis AG, GlaxoSmithKline plc., Cipla Inc., The Ritedose Corporation, Boehringer Ingelheim International GmbH, Shermco, Aurobindo Pharma, Circassia, Nostrum Laboratories Inc., Endo Pharmaceuticals Inc., Rhodes Pharmaceuticals LP, Mylan NV, Avet Pharmaceuticals Inc, Glenmark Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Tris Pharma, Inc., Celerion, Pharmaceutical Associates Inc., Allergan 등이 있으며, 국내 및 글로벌 기업도 있습니다. 시장 점유율 데이터는 글로벌, 북미, 유럽, 아시아 태평양(APAC), 중동 및 아프리카(MEA), 남미에 대해 각각 제공됩니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 개별적으로 제공합니다.

SKU-50400